Author

Andreas von Deimling

Primary ORCID profile (0000-0002-5863-540X · 8 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Andreas von DeimlingiD8 papers · German Cancer Research Center

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Andrea NistiD· 1 shared Constanze Schneider· 1 shared Daniel SpeideliD· 1 shared Florian Rothweiler· 1 shared Jindrich CinatliD· 1 shared Marco Mernberger· 1 shared Martin MichaelisiD· 1 shared Tamara Rothenburger· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Andrea NistORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacology & ToxicologybioRxivPreprintAug 30, 2018

TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

Martin Michaelis, Constanze Schneider, Florian Rothweiler…·Jindrich Cinatl

This study establishes MDM2 inhibitor-resistant AML sub-lines and finds that resistance arises from pre-existing TP53 mutations or de novo mutations, with variable drug sensitivity despite loss of p53 function.

DOI 10.1101/404475

humanbulk RNA-seq

𝕏 PostBluesky